Companies: 10,795·Total market cap: $144.5T
RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.

REPCFOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$7000
P/E Ratio
52W High$0.042835
52W Low$0.00001
Overview

RepliCel Life Sciences Inc. (REPCF) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · REPCF · as of Jun 9, 2026

Key Statistics

EPS (TTM)repcf eps ttm · repcf earnings per shareEarnings history
PE Ratio (TTM)repcf pe ratio ttm · repcf price to earningsPE Ratio deep dive
Revenue (TTM)repcf revenue ttm · repcf annual revenueFull revenue history
Dividend YieldNo Dividenddoes repcf pay dividends · repcf dividend yieldDividend history
Shares Outstandingrepcf shares outstanding · repcf floatShares outstanding history
Next EarningsTBArepcf earnings date · repcf next earningsEarnings history

About RepliCel Life Sciences Inc.

CEOAndrew Schutte
IPO DateMay 3, 2010
Employees1
CountryCA

RepliCel Life Sciences Inc. a biotechnology firm based in Vancouver, Canada, specializes in regenerative medicine. The company focuses on developing patient-specific cell therapies designed to addres…

what is replicel life sciences inc. · repcf stock overview · replicel life sciences inc. company profile · who is replicel life sciences inc. ceo · repcf OTC · replicel life sciences inc. headquarters · replicel life sciences inc. business segments

About Stock Overview & Key Data

RepliCel Life Sciences Inc. (REPCF) is a Healthcare company in the Biotechnology industry, listed on OTC since May 3, 2010. As of the latest trading session, REPCF stock price is $0.00, with a market capitalization of $7,000. The stock has returned — over the past 12 months and — year-to-date.

Frequently Asked Questions

As of the latest trading session, RepliCel Life Sciences Inc. (REPCF) stock price is $0.00. The stock is traded on OTC under the ticker symbol REPCF. The 52-week range is $0.00 – $0.04.

REPCF stock priceREPCF quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice